Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06569810

Real-world Registry Study of Red Light Treatment on Myopia Control: a Focus on Non-responders to Conventional Treatments

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
2,500 (estimated)
Sponsor
The Hong Kong Polytechnic University · Academic / Other
Sex
All
Age
8 Years – 16 Years
Healthy volunteers
Not accepted

Summary

This real-world observational registry study aims to assess the effectiveness of Repeated Low-Level Red Light (RLRL) therapy in controlling myopia progression among children aged 8 to 16 who have not responded to conventional treatments like Orthokeratology and atropine eyedrops. The primary focus is to determine if RLRL therapy can limit axial length (AL) elongation to less than 0.1mm per year and spherical equivalent refraction (SER) progression to less than 0.25 diopter per year, while also evaluating safety and visual outcomes.

Conditions

Interventions

TypeNameDescription
DEVICERepeated Low-Level Red Light (RLRL) therapyIn our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.

Timeline

Start date
2024-09-01
Primary completion
2026-08-01
Completion
2026-09-01
First posted
2024-08-26
Last updated
2024-08-26

Source: ClinicalTrials.gov record NCT06569810. Inclusion in this directory is not an endorsement.